Cugene

CUG288 Clin0 solid tumors; CUG279 Clin0 solid tumors; CUG105 Clin0 bladder cancer, solid tumors; 4 programs RD solid tumors

Cugene is a clinical-stage biotech founded in 2016 and based in Waltham Massachusetts. The team is developing next-generation therapeutics for cancer and autoimmune disease. Their novel molecules for autoimmune disease are designed to target specific cells and promote immune tolerance without causing off-target effects. In addition, their anti-cancer molecules are designed with advanced specificity as well to kill tumor cells without damaging healthy cells. They advertise a collaborative culture where their employees can grow and strive.

Jobs: